- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07947173
Phase 1 Trial to Assess Safety and Immunogenicity of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)
Randomized, Double-Blinded, Placebo-Controlled Phase 1 Clinical Trial to Assess the Safety and Immunogenicity of Two Doses of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) in Healthy Participants
Herpes zoster is caused by reactivation of varicella zoster virus. This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of self-replicating RNA (srRNA) herpes zoster vaccine JCXH-105. Eligible participants will receive 2 doses of study vaccine/placebo at planned dose levels and follow scheduled safety and immunogenicity follow-up visits. The goal of this study is to assess the safety profile and immune response induced by JCXH-105.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
(1) Gender: Male or female; (2) Age: ≥ 40 years of age at screening. (3) Status: Healthy participants. (4) Subject agrees not to receive any other herpes zoster vaccine while participating in this study.
(5) All Laboratory values required for screening prior to study enrollment are within normal limits or abnormal without clinical significance as judged by the investigator.
(6) Female participants must meet the following criteria:
-
Surgically sterile or postmenopausal for ≥ 2 years, or women of childbearing potential (premenopausal or postmenopausal for < 2 years) who have a negative pregnancy test and are willing to use effective contraception from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.
-
Agree not to breastfeed from the first administration of investigational vaccine/placebo to at least 3 months after the full-course vaccination.
(7) Male participants should meet the following criteria: agree to use effective contraception and not to donate sperms from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.
(8) Able to fully understand and voluntarily sign the informed consent form.
-
Exclusion Criteria:
-
(1) Participants who have a history of herpes zoster or are currently diagnosed with herpes zoster, or have a history of chickenpox, or a history of close contact with chickenpox/herpes zoster patients within 30 days before enrollment.
(2) History of chickenpox or herpes zoster vaccination. (3) Hypersensitivity to any component of the investigational vaccine/placebo, or any previous serious reaction to vaccination, or a history of serious allergic disease.
(4) Fever within 3 days prior to enrollment, acute illness or acute exacerbation of chronic illness within 7 days prior to enrollment, or taking antipyretic, analgesic, and anti-allergic drugs within 3 days prior to enrollment.
(5) History of significant cardiac disease, or myocarditis or pericarditis. (6) At present, participants with severe liver and kidney diseases, spleen dysfunction or asplenia, hypertension that cannot be controlled by drugs, diabetes with serious complications and other chronic diseases are currently suffering.
(7) Use of whole blood, blood products, or immunoglobulins within 3 months prior to vaccination or planned use during the study.
(8) Has received any inactive vaccine within 14 days prior to the first dose of vaccine.
(9) Received the following within 28 days prior to the first dose of vaccine: Any live/mRNA vaccine; Immunomodulators or immunosuppressive drugs; Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor; Receiving systemic corticosteroids for 3 or more consecutive days. (Note: Study participants are permitted to receive long-term systemic prednisone at a dose ≤10 mg/day, or systemic corticosteroids equivalent to prednisone. Topical medications such as ointments, eye drops, inhalants or nasal sprays are allowed, provided that the topical medications should not exceed the recommended dose in the instructions and there are no signs of systemic exposure.) (10) Have confirmed or suspected immunosuppression, immunodeficiency, or autoimmune disease.
(11) Positive screening test for HIV antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies.
(12) Known history of active or latent tuberculosis (Mycobacterium tuberculosis).
(13) Axillary temperature > 37.0 °C at enrollment. (14) Participation in another drug, device, or other vaccine clinical trial within 30 days prior to the first dose of investigational vaccine/placebo or planned participation during the study period.
(15) Participants with dermatologic condition that could affect local solicited adverse reaction assessments (e.g., tattoos, psoriasis, patches affecting skin over the deltoid area).
(16) Participants with contraindications to IM injection. (17) The investigator considers that there are other situations unsuitable for participating in this study, including but not limited to failure to participate in follow-up according to the study protocol.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Low-dose JCXH-105
Participants receive low dose of JCXH-105 |
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) |
|
Comparateur placebo: Low-dose placebo
Participants receive low dose of placebo |
Placebo (sodium chloride injection) as control |
|
Expérimental: Medium-dose JCXH-105
Participants receive medium dose of JCXH-105 |
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) |
|
Comparateur placebo: Medium-dose placebo
Participants receive medium dose of placebo |
Placebo (sodium chloride injection) as control |
|
Expérimental: High-dose JCXH-105
Participants receive high dose of JCXH-105 |
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) |
|
Comparateur placebo: High-dose placebo
Participants receive high dose of placebo |
Placebo (sodium chloride injection) as control |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Serious adverse events (SAEs)
Délai: From Day 1 post- administration through 360 days after the full-course vaccination
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
From Day 1 post- administration through 360 days after the full-course vaccination
|
|
Solicited local injection site adverse events
Délai: Within 14 days after each dose of investigational vaccine/placebo
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
Within 14 days after each dose of investigational vaccine/placebo
|
|
Solicited systemic adverse events
Délai: Within 14 days after each dose of the investigational vaccine/placebo
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
Within 14 days after each dose of the investigational vaccine/placebo
|
|
Unsolicited AEs
Délai: Within 30 days after each dose of the investigational vaccine/placebo
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
Within 30 days after each dose of the investigational vaccine/placebo
|
|
Laboratory parameters
Délai: On the third day after each dose of the investigational vaccine/placebo
|
Clinically significant abnormal changes of laboratory parameters compared with pre-vaccination |
On the third day after each dose of the investigational vaccine/placebo
|
|
Adverse events of special interest (AESIs)
Délai: From Day 1 post administration through 360 days after the full-course vaccination
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
From Day 1 post administration through 360 days after the full-course vaccination
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- JCXH-105-002
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .